Critical Outcome Technologies Announces Important New Mechanism of Action Data for COTI-2
Critical Outcome Technologies Inc.announced today new data that broadens the mechanism of action (MOA) of the Company's lead oncology asset, COTI-2, beyond AKT inhibition.
Effective in Cell Lines with Mutations in Cancer Suppressing Gene P53
London, Ontario September 20, 2012 / B3C newswire / - Critical Outcome Technologies Inc. (COTI) (TSX Venture: COT) announced today new data that broadens the mechanism of action (MOA) of the Company's lead oncology asset, COTI-2, beyond AKT inhibition. Previous preclinical MOA work on COTI-2 clearly showed that COTI-2 modulated the PI3K/AKT/mTOR pathway. However, new data derived from gene profiling and in vitro testing with COTI-2 indicates that the drug is particularly effective in treating cancer cell lines with p53 mutations, an effect that is not associated with AKT inhibitors.
"The effectiveness of COTI-2 based on the status of p53, a tumor suppressing gene, could make this compound and class an important new treatment for cancer, as at least 50% of human cancers harbor a p53 mutation," said Dr. Wayne Danter, President and CEO of COTI. "These findings improve our understanding of COTI-2's MOA and help clarify some of the positive results we have seen in earlier experiments and trials that were not explained by AKT inhibition alone."
COTI-2 has a chemical structure that puts it in a class of compounds referred to as thiosemicarbazones. The recognized class effects of thiosemicarbazones include metal ion chelation, the generation of reactive oxygen species (ROS), cancer cell apoptosis and, most recently, the ability to convert certain specific and common p53 mutations to wild type configuration with normal tumor suppressing function. Results from multiple animal models of human cancers indicate that these "class effects" of COTI-2, a third generation thiosemicarbazone, are central to understanding the outcome of these experiments in the context of their potential therapeutic implications.
The detailed analysis of COTI-2's gene profile and the in vitro test data produced the following results:
1.Multiple genes directly involved with metal binding and programmed cancer cell death were turned on, which is consistent with the known effects of this class of drugs.
2.COTI-2 was confirmed to bind to iron in a cell free assay, a common attribute of this class of compounds that leads to programmed cancer cell death.
3.The data obtained for 40 human cell lines revealed, in a detailed statistical analysis, that the presence of any p53 mutation strongly predicted cancer cell sensitivity at a very low concentration of COTI-2.
4.A simple and accurate exploratory predictive model of the relationship between p53 mutation status and COTI-2 in vitro activity was created using the currently available test data. This result suggests the p53 gene mutation status might be used to identify which cancers would be most responsive to COTI-2.
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance